GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,656.50
Bid: 1,656.50
Ask: 1,657.00
Change: 41.50 (2.57%)
Spread: 0.50 (0.03%)
Open: 1,631.00
High: 1,661.00
Low: 1,630.50
Prev. Close: 1,615.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

8 Jul 2022 15:53

RNS Number : 9017R
GSK PLC
08 July 2022
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

2,049.656

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Connor

b)

Position/status

President, Vaccines and Global Health

 

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

2,294.439

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

Chief People Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

5.658

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

232.599

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

124.792

 

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

Chief Commercial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

4,208.880

 

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

3,359.761

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

801.588

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

866.882

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Thomson

b)

Position/status

PCA of Mr P Thomson (President, Global Affairs)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

96.112

 

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO, ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 1 July 2022

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.9094

226.930

 

d)

Aggregated information

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-07-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSSFFLAEESEIW
Date   Source Headline
22nd Jan 20217:00 amRNSFDA approves ViiV Healthcare’s Cabenuva for HIV
20th Jan 20214:00 pmRNSDirector/PDMR Shareholding
20th Jan 20213:50 pmRNSDirector/PDMR Shareholding
20th Jan 20213:02 pmRNSDirector/PDMR Shareholding
19th Jan 20216:02 pmRNSDirector/PDMR Shareholding
15th Jan 20214:00 pmRNSDirector/PDMR Shareholding
15th Jan 20213:14 pmRNSDirector/PDMR Shareholding
13th Jan 20211:45 pmRNSDirector/PDMR Shareholding
11th Jan 202111:05 amRNSDirector/PDMR Shareholding
11th Jan 20219:16 amRNSDirector/PDMR Shareholding
4th Jan 202111:25 amRNSTotal Voting Rights
30th Dec 202011:52 amRNSDirector/PDMR Shareholding
23rd Dec 20202:44 pmRNSDirector/PDMR Shareholding
21st Dec 20207:00 amRNSViiV first long-acting HIV regimen approved in EU
11th Dec 20207:00 amRNSSanofi/ GSK update on COVID vaccine candidate
10th Dec 20205:51 pmRNSDirector/PDMR Shareholding
10th Dec 202011:55 amRNSBlock Listing Application
9th Dec 20203:04 pmRNSDirector/PDMR Shareholding
3rd Dec 20205:53 pmRNSDirector/PDMR Shareholding
1st Dec 20203:00 pmRNSTotal Voting Rights
27th Nov 20202:58 pmRNSGSK publishes provisional 2021 dividend dates
26th Nov 202012:35 pmRNSEMTN Supplementary Prospectus
25th Nov 202010:26 amRNSDirector/PDMR Shareholding
23rd Nov 20208:59 amRNSBlock listing Interim Review
19th Nov 20205:40 pmRNSHolding(s) in Company
17th Nov 20205:48 pmRNSDirector/PDMR Shareholding
12th Nov 20201:00 pmRNSMedicago GSK phase 2/3 study start
11th Nov 20203:08 pmRNSDirector/PDMR Shareholding
11th Nov 202011:13 amRNSDirector/PDMR Shareholding
9th Nov 20207:00 amRNSViiV’s cabotegravir superior for HIV prevention
4th Nov 20205:32 pmRNSDirector/PDMR Shareholding
4th Nov 20204:45 pmRNSDirector/PDMR Shareholding
3rd Nov 20204:09 pmRNSDirector/PDMR Shareholding
3rd Nov 20208:00 amRNSGSK sets new environmental goals
2nd Nov 20205:16 pmRNSDirector/PDMR Shareholding
2nd Nov 20203:59 pmRNSTotal Voting Rights
30th Oct 20205:08 pmRNSHolding(s) in Company
30th Oct 202012:53 pmRNSDirector/PDMR Shareholding
28th Oct 20205:46 pmRNSDirector/PDMR Shareholding
28th Oct 202012:00 pmRNS3rd Quarter Results
28th Oct 20207:00 amRNSSanofi and GSK support COVAX - 200m vaccine doses
22nd Oct 202012:34 pmRNSHolding(s) in Company
16th Oct 202012:18 pmRNSPositive CHMP opinion ViiV long-acting HIV regimen
14th Oct 20203:30 pmRNSDirector/PDMR Shareholding
14th Oct 20203:29 pmRNSDirector/PDMR Shareholding
13th Oct 20202:41 pmRNSDirector/PDMR Shareholding
13th Oct 20202:08 pmRNSDirector/PDMR Shareholding
13th Oct 20202:01 pmRNSDirector/PDMR Shareholding
13th Oct 20201:55 pmRNSDirector/PDMR Shareholding
13th Oct 20201:49 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.